Professor Michel Goldman
Founder of The Institute for Interdisciplinary Innovation in healthcare
Michel Goldman, MD, PhD, was the first Executive Director of the Innovative Medicines Initiative Joint Undertaking (IMI), from 2009 to 2014. With a budget of 2 billions € provided jointly by the European Federation of Pharmaceutical Industries and Associations and the European Commission, he was responsible for 59 public-private consortia in areas of major importance, including antimicrobial resistance, Alzheimer’s dementia, autism, diabetes, immuno-inflammatory disorders, chronic pulmonary diseases and drug safety.
From 1990 to 2008, he was the Head of the Department of Immunology-Hematology-Transfusion at the Erasme Hospital of the Université Libre de Bruxelles (ULB), and from 2009 to 2014 he serves as the first Director of the Institute for Medical Immunology at ULB.
Currently, Michel Goldman is Professor of Immunology and Pharmacotherapy at ULB. Furthermore, he is a member of the Board of Directors of CQDM (Canadian consortium for precompetitive research), of the Board of the Tuberculosis Vaccine Initiative and of the Strategic and Scientific Advisory Board of GenomeQuebec. He is also the Chairman of the Scientific Committee of Effimune S.A., a French biotechnology company.
Michel Goldman’s scientific achievements resulted in more than 400 articles in peer-reviewed journals and he was recognized as ISI Highly Cited Scientist in 2006 by the Thomson Institute for Scientific Information. In 2000 he received the Joseph Maisin Prize, a major award for clinical sciences delivered by the Fonds National de la Recherche Scientifique (Belgium) and he held in 2001 the Spinoza chair at the University of Amsterdam, the Netherlands. In 2007, Michel Goldman was awarded the degree of Doctor Honoris Causa of the Université Lille II, France.